Despite the development of novel chemotherapy regimens which are prolonging life in many patients with multiple myeloma, long term prognosis remains poor owing to the onset of chemoresistance. However, a number of available drugs have the potential to render this cancer more sensitive to chemotherapeutic agents, as suggested by the research abstracts posted here.